NEW TRENDS IN SYSTEMIC TREATMENT OF RENAL CANCER

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74–108.

2. Gleave ME, Elhilali M, Fradet Y et al. Interferon 7-lb compared with placebo in metastatic renal cell carcinoma. N Engl J Med 1998; 338: 1265–1271.

3. Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: Workgroup no. I. Union Inter­nationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80(5): 987–989.

4. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004; 10(18 Part 2): S6342—S6346.

5. Hutson TE, Figlin RA. Renal cell cancer. Cancer J 2007; 13(5): 282–286.

6. Kim WY, Kaelin WG. Molecular pathways in renal cell carcinoma — rationale for targeted treatment. Semin Oncol 2006; 33(5): 588–595.

7. Gnarra JR, Tory K, Weng Yet al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994; 7(1): 85–90.

8. Blakenship C, Naglich JG, Whalet et al. Alternate choice of initiation codon procedures a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Neogene 1999; 18: 1529–1535.

9. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2(9): 673–682.

10. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13(2): 167–171.

11. Jaakkola P, More DR, Tain YM et al. Targeting of HIF-α targeted to the von Hippel Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468–472.

12. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3(10): 721–732.

13. Harris AL. Hypoxia – a key regulatory factor in tumor growth. Nat Rev Cancer 2002; 2(1): 38–47.

14. Caldwell MC, Hough C, Purer S et al. Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF-a cytotoxicity. Oncogene 2002; 21: 929–936.

15. Sakamato S, Ryan AJ, Kyprianu N. Targeting vascu­lature in Urologic tumors: mechanistic and therapeu­tic significance. J Cell Biochem 2008; 103(3): 691–708.

16. Folkman J. Cinical applications of research on an­gio­genesis. N Engl J Med 1995; 333(26): 1757–1763.

17. de Vries C, Escobedo JS, Ueno H et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255(5047): 989–991.

18. Millauer B, Wizigmann-Voos S, Schnurch H et al. High affinity VEGF binding and developmental expression suggests flk-I as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72(6): 835–846.

19. Cho D, Signoretti S, Regan M et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007; 13: 5758–5763.

20. Le Tourneau C, Faivre S, Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008; 99(8): 1197–1203.

21. Faivre S, Kraeme G, Ramond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5(8): 671–688.

22. Brenner W, Farber G, Herget T et al. Loss of tumor suppressor protein PTEN during renal angiogenesis. Int J Cancer 2002; 99: 53–57.

23. Hamada K, Sasaki T, Koni PA et al. The PTEN/ PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005; 19(17): 2054–2065.

24. Gaba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by anti-angiogenesis involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128–135.

25. Arsham AM, Plas DR, Thompson CB et al. Phos­pha­tidylinositol 3-kinase/ Akt signaling is neither required for hypoxic stabilization of HIF-1 a nor sufficient for HIF-1 dependent target gene transcription.J Biol Chem 2002; 277(17): 15162–15170.

26. Chow LQ, Eckhardt SG. Sunitinib from rational design to clinical efficacy. J Clin Oncol 2007; 25(7): 884–896.

27. Faivre S, Delbaldo, Vera K et al. Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24(1), 25–35.

28. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet derived growth factor receptor in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24(1): 16–24.

29. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295(21): 2516–2524.

30. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17(8): 2530–2540. This study established a prognostic index for advanced renal cell carcinoma (RCC) in the cytokine era.

31. Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178(5): 1883–1887.

32. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal cell carcinoma. N Engl J Med 2007; 356(2): 115–124. This large-scale randomized Phase III trial demonstrated the clinical efficacy of sunitinib over IFN-α as front-line therapy for metastatic (m)RCC.

33. Figlin TA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN) a as first line treatment of metastatic renal-cell carcinoma (mRCC). J Clin Oncol 2008; 26(Suppl.): 5256. (Abstract 5024).

34. Gore M, Szczylik C, Porta C et al. Sunitinib in me­ta­static renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis. Eur J Cancer 2007; 5(Suppl): 299. (Abstract 4503).

35. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099–7109.

36. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24(16): 2505–2512.

37. Escudier B, Szcylik C, Demkov T et al. Rando­mi­zed Phase II trial of the multikinase inhibitor sorafenib versus interferon (IFN) in treatment naive patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2002; 24(Suppl. 18): 4501.

38. Escudier B, Eisen T, Stadler WM et al. TARGET Study Group: sorafenib in advanced clear cell renal carcinoma. N Engl J Med 2007; 356:125–134. This large-scale, placebo-controlled, randomized Phase III study demonstrated the clinical efficacy of sorafenib in the second-line setting in clear-cell mRCC.

39. Bukowski RM, Eisen T, Szcylik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomar­ker analysis. J Clin Oncol 2007; 25(Suppl.): 5023.

40. Beck J, Procopio E, Verzoni S et al. Large open label non-comparative clinical experience trial of the multi-targeted kinase inhibitor sorafenib in European patients with advanced RCC. J Clin Oncol 2008; 26(Suppl). (Abstract 1621).

41. Shepard DR, Rini BI, Garcia A et al. A multicenter prospective trial of sorafenib in patients with metastatic clear cell renal cell carcinoma refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008; 26(Suppl.). (Abstract 5123).

42. Szczylik C, Demkow T, Staehler M et al. Rando­mized Phase II trial of first line treatment with sorafenib versus IFN in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007; 25(Suppl). (Abstract 5025).

43. Atkins MB, Hidalgo M, Stadler WM et al. Rando­mized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22(5): 909–918.

44. Hudes G, Carducci M, Tomczak P et al. Temsiro­limus, interferon a or both for advanced renal cell carcinoma. N Engl J Med 2007; 356(22): 2271–2281. This Phase III randomized placebo- controlled trial demonstrated the significant improvement in overall survival for temsirolimus monotherapy in high-risk mRCC patients compared with IFN-α or as combination therapy.

45. Motzer RJ, Michaelson MD, Hutson TE. Sunitinib versus interferon-a as first line treatment of metastatic renal cell carcinoma: updated efficacy and safety results and further analysis of prognostic factors. fur. J Cancer 2007; 5(Suppl.). (Abstract 301).

46. Jac J, Giessinger S, Khan M et al. A Phase II trial of RAD001 in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007; 25(Suppl.). (Abstract 5107).

47. Motzer RJ, Escudier B, Ouard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomized, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008). in tumor growth. Nat Rev Cancer 2002; 2: 38–47.

48. Yang JC, Haworth L, Sherry RM et al. A rando­mized trial of bevacizumab an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med 2003; 349(5): 427–434.

49. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus IFN α-2a for treatment of metastatic renal cell carcinoma: a randomised, double blind Phase III trial. Lancet 2007; 370: 2103–2111.

50. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon a compared with interferon a mo­no­therapy in patients with metastatic renal cell carcinoma: CALGB. J Clin Oncol 2008; 26(33): 5422–5428. This Phase III randomized trial confirmed the addition of bevacizumab and IFN-α results in improved PFS compared with placebo and IFN-α.

51. Chouetn TK, Plantade A, Elson Petal. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26(1): 127–131. Largest detailed retrospective series of VEGF targeted therapies of sunitinib and sorafenib in non-clear-cell mRCC.

52. Dutcher J, de Souza P, McDermott DR et al. Effect of temsirolimus versus interferon-a on survival of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26(2): 202–209.

53. Schrader AJ, Olbert PJ, Hegele A et al. Metastatic non-clear cell renal cell carcinoma: current therapeutic options. BJU Int 2008; 101(11): 1343–1345.

54. Mian BM, Bhadkamkar N, Slaton JW et at. Prog­nostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167: 65–70.

55. Beck J, Bajetta E, Escudier B et al. Large open label, non-comparative, Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer 2007; 5(Suppl); 300. (Abstract 4506).

56. Golshayan AR, George S, Heng DY et at. Meta­static renal cell carcinoma (mRCC) patients with sarcomatoid features treated with VEGF-targeted the­rapy. J Clin Oncol 2008; 26(Suppl.). (Abstract 5102).

57. Whorf JD, Hainsworth DR, Spigel DA et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008; 26(Suppl.). (Abstract 5010).

58. Hainsworth JD, Sosman JA, Spigel DR et al. Treat­ment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23(31): 7889–7896.

59. Bukowski RM, Kabbinavar FF, Figlin RA et al. Ran­do­mized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25(29): 4536–4541.

60. George DJ, Michaelson MD, Rosenberg JE et al. Phase II trial of sunitinib in bevacizumab refractory metastatic renal cell cancer: updated results and analysis of circulating biomarkers. J Clin Oncol 2007; 25(Suppl.). (Abstract 5035).

61. Rixe O, Bukowski RM, Michaelson MD et al. Axiti­nib treatment in patients with cytokine refractory metastatic renal cell cancer: a Phase II study. Lancet Oncol 2007; 8(11): 975–984.

62. Rini B, Wilding GT, Hudes G et al. Axitinib (AG-013736; AG) in patients with metastatic renal cell cancer refractory to sorafenib. J Clin Oncol 2007; 25(18S): 5032.

63. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007; 9(2): 115–119.

64. Hutson TE, Davis ID, Machiels JP et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma. Interim results of a Phase II randomized discon­tinuation trial. J Clin Oncol 2007; 25(Suppl.): 5031.

65. Bhargava P, Esteves O, Lipatov ON et al. Activity and safety of AV-951, a potent and selective VEGFRI, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma: interim results of a Phase II randomized discontinuation trial. Presented at: ASCO Genitourinary Cancers Symposium. Orlando, FL, USA. 26-28 February 2009. (Abstract 283).

66. Bellmunt J. The oncolgist's view: targeted therapies in advanced renal cell carcinoma. Eur Urol 2008; 7(Suppl. 2): 55–62.

67. Hutson TE, Figlin RA, Kuhn JG et al. Targeted the­rapies for metastatic renal cell carcinoma: an over­view of toxicity and dosing strategies. Oncologist 2008; 13(10): 1084–1096.

68. Rini BI, Choueiri TK, Elson P et al. Sunitinib indu­ced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008; 113(6): 1309–1314.

69. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon ct-2b compared with interferon ct-2b alone for metastatic renal cell cancer. N Engl J Med 2001; 345: 1655–1659.

70. Nanus DM, Pfeffer LM, Bander NH et al. Antipro­liferative and antitumor effects of a interferon in renal cell carcinomas: correlation with the expression of a kidney associated differentiation glycoprotein. Cancer Res 1990; 50(14): 4190–4194.

71. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 1: CD001425.

72. Rosenberg SA. Progress in human tumor immu­nology and immunotherapy. Nature 2001; 411(6835): 380–384.

73. Fehniger TA, Cooper MA, Caliguiri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13(2): 169–183.

74. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin therapy. J Clin Oncol 1995; 13(3): 688–696.

75. Fisher RI, Rosenberg SA, Fyfe G. Long term survival update for high dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6(Suppl. I): S55–S57.

76. McDermott DF, Regan M, Clack JI et al. Rando­mized Phase III trial of high dose interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(1): 133–141.

77. Yang JC, Sherry RM, Steinberg SM et al. Rando­mized study of high dose and low dose interleukin-2 in patients with metastatic renal cell cancer. J Clin Oncol 2003; 21(16): 3127–3132.

78. Schmidinger M, Hejna M, Zielinski CC. Aldes­leu­kin in advanced renal cell carcinoma. Expert Rev Anticancer Ther 2004; 4(6): 957–980.

79. Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2 and interferon a-2a based immunotherapy in advan­ced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22: 1188–1194.

80. Boccardo F, Rubagotti A, Canabbia Let al. Inter­leu­kin-2, interferon-a and interleukin-2 plus interferon-a in renal cell carcinoma. A randomized Phase II trial. Tumori 1998; 84(5): 534–539.

81. Henriksson R, Nilsson S, Colleen S et al. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, a-interferon and tamo­xifen. Br J Cancer 1998; 77: 1311–1317.

82. Negrier S, Escudier B, Lasser C et al. Recom­binant human interleukin-2, recombinant human interferon a-2a, or both in metastatic renal cell carcinoma. Grouppe Francois d'Immunotherapie. N Engl J Med 1998; 338: 1272–1278.

83. Klatte T, de Martino M, Shuch B et al. Long term outcome of interleukin-2 based immunotherapy for the treatment of metastatic renal cell carcinoma. J Clin Oncol 2008; 26(Suppl.). (Abstract 5119).

84. Bui MH, Seligson D, Han KR et al. Carbonic anhyrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9(2): 802–811.

85. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res 2005; 11(10): 3714–3721.

86. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228–247.

87. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-α as first line treatment of metastatic renal cell carcinoma (mRC.C). J Clin Oncol 2008; 26(Suppl.). (Abstract 5024).

88. Ljunberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur Urol 2007; 51(6): 1502–1510.

89. Motzer RJ, Bacik J, Murphy BA et al. Interferon a as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20(1): 289–296.

90. Szczylik C, Demkov T, Staehler M et al. Rando­mi­zed Phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007; 25(Suppl.). (Abstract 5025).

91. Mills EJ, Rachlis B, O'Regan C et al. Metastatic renal cell cancer treatments: an indirect men-analysis. BMC Cancer 2009; 9: 34–42. This meta-analysis demonstrated the superior efficacy of sunitinib over sorafenib and bevacizuntab plus IFN-α, in terms of PFS in clear-cell mRCC, using an indirect comparison methodology.

92. Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009; 181(2): 518–523.

93. Jonasch E, Tannic N. Adjuvant and neoadjuvant the­ra­py in renal cell carcinoma. Cancer J 2008; 14(5): 315–319.

94. Kirkali Z. Editorial Comment on: prognostic va­lue of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol 2009; 55(2): 460.

Website 101. National Comprehensive Cancer Net­work: NCCN clinical practice guidelines in oncology: kidney cancer v.1.2008 (2008) www.nccn.org/profes­sionals/physician_gls/PDF/kidney.pdf